Search

Your search keyword '"Lorefice, R"' showing total 9 results
Start Over Author "Lorefice, R"
9 results on '"Lorefice, R"'

2. Female sexuality and vaginal health across the menopausal age

Author

Angelo, Cagnacci, Martina, Venier, Anjeza, Xholli, Chiara, Paglietti, Salvatore, Caruso, for the ANGEL Study Group: Algeri, M, Donvito, G, Bastianelli, C, Cagnacci, A, Palma, F, Napolitano, A, Capobianco, G, Dessole, S, Cianci, A, Caruso, S, Cinque, B, Dati, S, Cioffi, Gp, Costantino, D, D’Anna, R, De Leo, V, Di Carlo, C, Di Francesco, A, Di Renzo, G, Baldoni, A, Lorefice, R, Ferrazzi, E, Valente, I, Gambacciani, M, Gambera, A, Greco, P, Bonaccorsi, G, Guaschino, S, Tredici, Z, Labanchi, R, Chiacchio, A, Lanzone, A, Villa, P, Lello, S, Capozzi, A, Leo, L, Salvatores, M, Marchesoni, D, Vogrig, E, Perrone, A, Segatore, M, Pallone, B, Petruzzelli, F, Libergoli, A, Roccamorena, A, Scarciglia, M, Serracchioli, R, Meriggiola, C, Surico, N, Zorzeti Cigna, S, Zullo, F, Delfini, R, and Giovannini, P

Subjects
Adult, medicine.medical_specialty, Cross-sectional study, General Mathematics, media_common.quotation_subject, Vaginal Diseases, 030209 endocrinology & metabolism, Human sexuality, Orgasm, NO, 03 medical and health sciences, 0302 clinical medicine, Atrophy, FSFI, Menopause, Perimenopause, Sexuality, Vaginal atrophy, Vaginal dryness, Sexuality, FSFI, Vaginal atrophy, Vaginal dryness, Menopause, Perimenopause, medicine, Prevalence, Humans, media_common, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics, Applied Mathematics, Obstetrics and Gynecology, Middle Aged, medicine.disease, Sexual Dysfunction, Physiological, Sexual dysfunction, Cross-Sectional Studies, Dyspareunia, Multicenter study, Italy, Vagina, FSFI, Menopause, Perimenopause, Sexuality, Vaginal atrophy, Vaginal dryness, Observational study, Female, medicine.symptom, business
Abstract

The primary aim was to evaluate changes in female sexuality across the menopausal period, and the secondary objective was to test the associations of female sexuality domains with vaginal atrophy and its symptoms.A cross-sectional multicenter study was performed involving 518 women, 40 to 55 years of age, consulting outpatient gynecological services at 30 centers across Italy. Vaginal atrophy was identified by the contemporaneous presence of a pH5, subjective vaginal dryness, and an objective sign. The relationships between vaginal atrophy and its main symptoms (vaginal dryness and dyspareunia), and Female Sexual Function Index (FSFI) score and its domains (desire, arousal, orgasm, dyspareunia, lubrication, and sexual satisfaction) were analyzed.The prevalence of sexual dysfunction, as defined by a FSFI score26.55, was 70.6%, increasing from 55% in the years 40 to 45, to 82.8% (P 0.01) in the years 52 to 55 of age. Mean FSFI score decreased from 40 to 45, to 46 to 48 years of age (23.13 ± 9.76 vs 19.49 ± 9.88; P 0.05), and from 48 to 51, to 52 to 55 years of age (21.3 ± 8.06 to 17.59 ± 9.11; P 0.01). Independent determinants of FSFI were age, vaginal atrophy, and the presence of vaginal dryness and dyspareunia (R2 0.208; P = 0.011). FSFI score was independently correlated (R2 0.116) with weight (CR -0.067; 95% confidence interval [CI] -0.126, -0.006; P 0.032), menopausal status (CR -2.406; 95% CI -4.180, -0.63; P 0.008), and vaginal dryness (CR -5.647; 95% CI -7.677, -3.618; P 0.0001). Vaginal dryness was the only variable correlated independently with each FSFI domain, including desire (also correlated with menopausal status), arousal (with age and menopausal status), lubrication (with age), orgasm (with age), satisfaction (with vaginal atrophy and being an ex-smoker), and dyspareunia (with age and spontaneously referred dyspareunia).In the perimenopausal years, FSFI score decreases and sexual dysfunction increases by about 30%. Vaginal dryness is the symptom of vaginal atrophy most closely related to all domains of female sexuality.

Published
2019

3. The effect of menopause on blood lipid and lipoprotein levels

Author

de aloysio, D, Gambacciani, M, Meschia, M, Pansini, F, Bacchi Modena, A, Bolis, Pf, Massobrio, M, Maiocchi, G, Peruzzi, E, Nencioni, T, Ciammella, M, Bonaccorsi, G, Morano, D, Viglino, S, Artoni, G, Grassini, E, Radici, G, De Cicco, F, Ronsisvalle, E, Marcacci, B, Perrone, P, De PAoli, D, Colacurci, N, De Franciscis, P, Lodico, G, Ferreri, R, Loizzi, V, Giacomelli, P, Benetello, E, Salmaggi, P, Coniglio, E, Giussani, E, Comi, R, Grimaldi, E, Mangino, Fp, Bucciantini, S, Checcucci, V, Nappi, C, Affinito, P, Campagnoli, C, Lanza, M, Galbiati, G, Albini, D, Lentini, G, Civallelci, S, Galbignani, E, Franchi, M, Terreni, Mg, Cicoli, C, Pulisca, S, Chionna, R, Marabini, R, Cordopatri, A, Spadaro, I, Cagnacci, Angelo, Volpe, A, De Leo, V, La MArca, A, Camanni, F, Manieri, C, Scognamiglio, P, Romani, L, Cargiaghe, S, Mannu, L, Masi, P, Fattorini, G, Bersellini, B, Bianicotti, L, Marchesoni, D, Dal Pozzo, M, Ramazzotto, F, Stegher, C, Molteni, B, Molteni, E, Lombardo, R, Galati, G, Sironi, A, Ranchet, G, Belloni, C, Proietti, C, Lorefice, R, Menozzi, G, Carunchio, P, Rovetta, E, Gallo, M, De Luigi, G, Righetti, G, Favaro, P, Gentile, E, Flangini, O, De Stefani, L, Sciacchitano, Sg, Catrini, R, Bartiromo, F, Bruno, M, Puggioni, Gf, Sionis, L, Agostinelli, D, Tajani, E, Mercuri, G, and Petronio, P.

Subjects
Menopause, Lipid, Cholesterol
Published
1999

9. Comparative bioavailability of two tablet preparations of diltiazem in healthy volunteers.

Author

De Bernardis E, Candido P, Lorefice R, Picari M, and Rizza V

Subjects
Adult, Biological Availability, Chromatography, High Pressure Liquid, Delayed-Action Preparations, Diltiazem administration & dosage, Female, Humans, Male, Middle Aged, Tablets, Diltiazem pharmacokinetics
Abstract

Comparative bioavailability of two formulations of diltiazem (Dilzene, CAS 42399-41-7), a calcium antagonist, was evaluated on 10 healthy volunteers (5 males and 5 females) in a cross-over study. A single dose of 120 mg of diltiazem was administered to the volunteers in the form of either two 60-mg tablets or a 120 mg controlled-release tablet. Plasma concentrations of diltiazem over a 24-h time interval were determined by HPLC analysis. Results of this investigation demonstrate that the controlled-release formulation of diltiazem has a lower Cmax value when compared to the 60 mg conventional tablet formulation, but a longer tmax and a superimposable AUC.

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results